SCHEMBL12434229

SCHEMBL12434229

COc1ccccc1CCNC(=O)c1ccccc1-c1ccccc1CNC(=O)OC(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 7/20 0.69
HPGD P15428 4/20 0.52
CDK4 P11802 1/20 0.52
CCND1 P24385 1/20 0.52
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
RCE1 Q9Y256 1/20 0.48
KCNA3 P22001 2/20 0.48
KCNK3 O14649 2/20 0.48
KCNH2 Q12809 1/20 0.47
IDO1 P14902 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434478 0.86 KCNA5 (0.73) KCNA5KCNA3KCNK3KCNH2
SCHEMBL12434226 0.86 KCNA5 (0.76) KCNA5ALDH1A1KCNA3KCNK3KCNH2
SCHEMBL8419482 0.83 MTNR1A (0.67) HPGDMTNR1AMTNR1BKMT2AALDH1A1
SCHEMBL12434230 0.82 KCNA5 (0.64) KCNA5HPGDKMT2AALDH1A1KDM4E
SCHEMBL12434168 0.82 KCNA5 (1.00) KCNA5KCNA3KCNK3
SCHEMBL12434227 0.82 KCNA5 (0.61) KCNA5HPGDKMT2AALDH1A1KDM4E
SCHEMBL12434173 0.82 KCNA5 (0.71) KCNA5KDM4EKCNA3KCNK3KCNH2
SCHEMBL3417084 0.80 HPGD (0.60) HPGDKMT2AALDH1A1KDM4ERCE1
SCHEMBL12434473 0.80 KCNA5 (0.71) KCNA5HPGDKMT2AALDH1A1KCNA3
SCHEMBL12434153 0.80 KCNK3 (0.67) KCNA5KMT2AALDH1A1KCNA3KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885HPGD 3454/4885CDK4 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.